English | Spanish
ecancer
Login Register
The content on this site is intended for healthcare professionals only
  • Home
  • News
  • Journal
  • Video
  • elearning
  • Conferences
  • About us
Breast
Prostate & urology
Lung & pleura
Colorectal & gastro
Melanoma & skin
Head & neck
Ovary & gynaecology
+ -
Bone
Brain & nervous system
Haematology oncology
Hepatobiliary pancreatic
Paediatric
Neuroendocrine
Sarcomas

ecancer and the City Cancer Challenge have formed an educational collaboration. Learners who are part of the City Cancer Challenge's project can access additional education provided by them.

Please login or register. Then you can use this button to confirm you are part of this project.
Register for free Already have an account? Login
Videos [420]
News [1195]
Articles [53]
Editorials [2]
Conferences [49]
elearning [0]
Tumour ‘signatures’ could provide key to more accurate treatment for deadliest cancers
Tumour ‘signatures’ could provide key to more accurate treatment for deadliest cancers
Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy
Novel DNA aptamer for CYP24A1 inhibition ID’d, possible target for anticancer therapy
Age-related lung changes provide pathway for metastatic growth of dormant melanoma cancer cells
Age-related lung changes provide pathway for metastatic growth of dormant melanoma cancer cells
Ultrasound-guided microbubbles boost immunotherapy efficacy
Ultrasound-guided microbubbles boost immunotherapy efficacy
The paired perils of breast cancer and diabetes
The paired perils of breast cancer and diabetes
ECOG-ACRIN research highlights at ASCO 2022
ECOG-ACRIN research highlights at ASCO 2022
ASCO 2022: Targeting p53 pathway shows promise for patients with Merkel cell carcinoma
ASCO 2022: Targeting p53 pathway shows promise for patients with Merkel cell carcinoma
ASCO 2022: Novel immunotherapy combination improved survival in patients with metastatic melanoma
ASCO 2022: Novel immunotherapy combination improved survival in patients with metastatic melanoma
ASCO 2022: Desmoplastic melanoma responds to PD-1 blockade immunotherapy
ASCO 2022: Desmoplastic melanoma responds to PD-1 blockade immunotherapy
Patient voices a good predictor of cancer treatment outcomes
Patient voices a good predictor of cancer treatment outcomes
<12345...120>

More from ecancer

Stay up to date with our ecancer newsletter

Learn more

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

Learn more

Support ecancer's work by making a donation

  • Contact
  • Projects
  • Cookie Policy
  • Terms of Use
  • Privacy Policy
  • Follow ecancer on Facebook
  • Follow ecancer on Twitter
  • Follow ecancer on Linkedin
  • Subscribe to the ecancer YouTube channel
© 2022 ecancer, all rights reserved
UK registered charity number: 1176307